Hsia Daniel S, Younes Naji, Ghosh Alokananda, Kazemi Erin J, Krause-Steinrauf Heidi, Buse John B, Baker Chelsea, Brown-Friday Janet, Diaz Elsa, Diner Jamie, Groessl Erik J, Legowski Elizabeth A, Mariash Cary N, Waltje Andrea H, Wexler Deborah J, Martin Catherine L
Pennington Biomedical Research Center, Baton Rouge, LA.
Division of Endocrinology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA.
Diabetes Care. 2025 Jul 1;48(7):1288-1294. doi: 10.2337/dc24-2839.
To compare rates of and risk factors for hospitalizations among Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) participants taking metformin and randomly assigned to insulin glargine U-100, glimepiride, liraglutide, or sitagliptin.
Intention-to-treat (ITT) (N = 5,047) and on-assigned-treatment (AT) (N = 4,830) data sets were used. Baseline differences between those hospitalized versus those not hospitalized were assessed. Kaplan-Meier analysis was used to determine incidence for time to first hospitalization, and log-rank tests were used to determine treatment group differences. Time-to-event analyses were used to examine factors affecting subsequent hospitalization risk.
During GRADE, 1,636 participants (32.4%) were hospitalized at least once and 751 (14.9%) were hospitalized more than once. Hospitalized participants were older, less likely to be Hispanic, more likely to be White, and more likely to have a history of hypertension and had higher baseline BMI. There were no treatment group differences in incidence for time to first hospitalization in the ITT data set (P = 0.148), but a reduced hazard rate was observed for those taking liraglutide versus those taking glimepiride in the AT data set (hazard ratio 0.78 [95% CI 0.66, 0.92]; P = 0.022). Factors increasing the risk for subsequent hospitalizations included meeting the secondary outcome (HbA1c >7.5%, confirmed), each prior hospitalization, and change from assigned treatment (29%, 41%, and 56% increase in risk, respectively). Assignment to liraglutide versus glimepiride reduced this risk by 13%.
Hospitalizations were common in GRADE, and rates were nearly identical across treatment groups. The small, but significant, reduction in risk for subsequent hospitalizations among participants assigned to liraglutide versus glimepiride may influence treatment decisions in populations similar to GRADE participants.
在糖尿病血糖降低方法:一项比较疗效研究(GRADE)中,比较服用二甲双胍并随机分配接受甘精胰岛素U-100、格列美脲、利拉鲁肽或西他列汀治疗的参与者的住院率及危险因素。
使用意向性治疗(ITT)(N = 5,047)和指定治疗(AT)(N = 4,830)数据集。评估住院者与未住院者之间的基线差异。采用Kaplan-Meier分析确定首次住院时间的发生率,采用对数秩检验确定治疗组间差异。采用事件发生时间分析来检查影响后续住院风险的因素。
在GRADE研究期间,1,636名参与者(32.4%)至少住院一次,751名(14.9%)住院不止一次。住院参与者年龄较大,西班牙裔可能性较小,白人可能性较大,更有可能有高血压病史且基线体重指数较高。在ITT数据集中,首次住院时间的发生率在各治疗组之间无差异(P = 0.148),但在AT数据集中,与服用格列美脲的参与者相比,服用利拉鲁肽的参与者的风险率降低(风险比0.78 [95% CI 0.66, 0.92];P = 0.022)。增加后续住院风险的因素包括达到次要结局(糖化血红蛋白>7.5%,已确认)、每次既往住院以及与指定治疗的改变(风险分别增加29%、41%和56%)。与格列美脲相比,分配接受利拉鲁肽治疗可使该风险降低13%。
在GRADE研究中住院情况常见,各治疗组的住院率几乎相同。与格列美脲相比,分配接受利拉鲁肽治疗的参与者后续住院风险虽有小幅但显著降低,这可能会影响与GRADE参与者类似人群的治疗决策。